CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS
1 other identifier
interventional
39
1 country
1
Brief Summary
Patients with multiple sclerosis (MS) may show chronic signs of optic neuropathy (CON) that may follow acute optic neuritis (secondary form of CON, S-CON) or occur independently of any acute demyelinating lesion of the optic nerve (primary form of CON, P-CON). In both S-CON and P-CON, a long term progressive ganglion cell axonal loss occurs. This axonal damage could be secondary to retrograde atrophy of axons within plaques of demyelination or a primary progressive degeneration of ganglion cells, but the underlying physiopathology has not been fully questioned in the different profile types of CON. In this project, investigators aim at understanding the pathophysiology of S-CON and P-CON, i.e. secondary to demyelination or primary degeneration, in patients complaining of persistent visual complaints. In a first cross sectional study, 30 MS patients with mild to moderate P-CPON or S-CON and 30 age-matched control subjects will perform an extensive neuro-ophthalmological assessment including clinical examination, visual evoked potentials (pattern and low contrast), electroretinogram (pattern and multifocal ERG), OCT (peripapillary and macular volume scan segmentation protocols) and MRI of the optic nerve. In these patients with mild to moderate CON, investigators aim at differentiating patients showing predominant demyelination from those showing pure or predominant axonal degeneration. Visual function assessment and degree of axonal degeneration will be compared and correlated in the two types of underlying pathophysiology and in the group of control subject. In a following longitudinal study, the patients will be re-assessed a year later in order to evaluate the progression of CON in both profile types. Our hypothesis would be that visual function and progression is worse in the degeneration group as compared to the demyelination group. This study should help to find reliable measures of the pathophysiology of CON and correlate it with the long-term visual prognostic of the disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2014
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 25, 2014
CompletedStudy Start
First participant enrolled
September 1, 2014
CompletedFirst Posted
Study publicly available on registry
September 7, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2016
CompletedSeptember 3, 2025
August 1, 2025
1.9 years
June 25, 2014
August 26, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from Day0 15' P100 VEP latency at one year
15' VEP latency may be the best outcome that allow differentiating patients from controls, and each of the sub-group of patients
D0 and one year
Secondary Outcomes (6)
Change from Day0 100%, 2.5% and 1.25% ETDRS Visual Acuity at one year (composite measure)
D0 and one year
Change from Day0 Visual field macular threshold and corrected mean visual field deficit at one year (composite measure)
D0 and one year
change frome Day0 NEI-VFQ 25 composite score and 10-item score at one year (composite measure)
D0 and one year
Change from Day0 N75, P100, N135 VEP latency and amplitude; P50, N95 ERG latency and amplitude; p1 mERG latency and amplitude at one year (composite measure)
D0 and one year
Change from Day0 OCT peripapillary RNLF thickness and Ganglion cell layer average thickness on macular dense volume at one year (composite measure)
D0 and one year
- +1 more secondary outcomes
Study Arms (2)
patients
OTHERpatients with chronic optic neuropathy in multiple sclerosis
Controls
OTHERhealthy volunteers
Interventions
Eligibility Criteria
You may qualify if:
- All patients may have a clinically definite, laboratory-supported diagnosis of multiple sclerosis according to the Mac Donald criteria (2010).
- All patients may present a chronic visual complaint.
- All patients may present mild to moderate chronic optic neuropathy (cf infra)
- All patients may not have recent acute optic neuritis (\<2 years)
- All patients will be informed about the design and purpose of the study, and all will give their informed, written consent to the protocol, which may have been approved by the local ethics committee.
- Age: \> 18
- Able to understand the instructions
- Having a health coverage
- Able to sit down for 1 hour Diagnosis of mild to moderate chronic optic neuropathy
- For the diagnosis of optic neuropathy, patients will have to meet 3 of the 6 next criteria:
- Far Visual Acuity (ETDRS charts, 100% contrast) \< 85 letters
- Far Visual Acuity (ETDRS charts, 2.5% contrast) \< 60 letters
- Mean visual field defect on static perimetry\> 2dB
- Mean pRNFL in OCT \< 80 µ.
- Color vision score \> 35
- +8 more criteria
You may not qualify if:
- Ophthalmological
- Other ophthalmological disorder that could impair corrected visual acuity (Maculopathy, Retinopathy…)
- Ocular instability in primary position of gaze
- Neurological
- Ongoing seizure
- Severe handicap that does not allow sitting down position for 1 hour
- General
- Unstable medical state
- Severe renal insufficiency
- Allergy to gadolinium
- Claustrophobia
- Implanted electrical stimulator (pace maker)
- Metallic prosthesis or orthesis, cochlear implants
- Intraocular foreign material
- Pregnancy (on questioning)
- +12 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hospices Civils de Lyonlead
- Fondation pour la Recherche Médicalecollaborator
Study Sites (1)
Unité de Neuro-Ophtalmologie - Hôpital Neurologique - HOSPICES CIVILS DE LYON
France, BRON, 69677, France
Related Publications (1)
Physiopathologie de la Neuropathie Optique Chronique de la SEP " Lucie ABOUAF, François DURAND-DUBIEF, Sandra VUKUSIC, Alain VIGHETTO, Caroline TILIKETE. Communication orale aux 3e journée des Neurosciences de l'Hôpital Neurologique le jeudi 24 septembre 2015, Institut des Sciences Cognitives, Lyon.
BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Caroline TILIKETE, MD
Unité de Neuro-Ophtalmologie - Hôpital Neurologique - HOSPICES CIVILS DE LYON - France
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 25, 2014
First Posted
September 7, 2015
Study Start
September 1, 2014
Primary Completion
August 1, 2016
Study Completion
August 1, 2016
Last Updated
September 3, 2025
Record last verified: 2025-08